光明图片/视觉中国 转自：光明日报 （来源：光明日报） 光明图片/视觉中国 光明图片/视觉中国 【幸福处方】 随着健康意识的增强，各式各样的营养膳食补充剂受到人们的青睐，其中，深海鱼油、南极磷虾 油、藻油等营养油胶囊，尽管普遍价格不菲，但却很是热销。 "有助于维护血脂健康水平""心脑血管日常养护""呵护心脑眼"……打开各大电商平台，保健品选项 中大多这样标注它们的功效。在买家评论区，可以看到，除了一些老年人将其作为调节血脂和心血管病 的日常保健品外，也不乏大量中青年买家。那么，无论是什么"油"，它们的健康功效到底如何？不同人 群应该怎么吃？记者采访了相关专家—— 补"油"本质上是补"DHA+EPA" 无论是深海鱼油、南极磷虾油，还是藻油、海豹油，仔细梳理它们的产品介绍和功效说明，可以发 现，富含DHA和EPA是它们共同的卖点。那么，这两种物质到底有什么营养功效？ "DHA和EPA都属于脂肪中的多不饱和脂肪酸，具体归类为omega－3或n-3多不饱和脂肪酸。"中国 农业科学院油料作物研究所油料品质与加工利用创新团队博士陈力介绍，目前国际上已有大量的研究成 果证明，n-3多不饱和脂肪酸既能提供能量，也是人体细胞结 ...

Core Viewpoint - Qingmu Technology, a leading domestic internet e-commerce service provider, is enhancing its market competitiveness through a significant acquisition in the health sector by acquiring 65.83% of Vitalis Pharma AS for 2.12 billion RMB [2][3]. Acquisition Details - The acquisition will be executed by Qingmu's wholly-owned subsidiary, Qingmu PTE. LTD., in two steps: purchasing 49.0662% of Vitalis for approximately 1.06 billion RMB and subscribing to 32.9157% of newly issued shares for the same amount [3]. - Vitalis, established in 2005 in Oslo, Norway, specializes in high-end dietary supplements, including products like seal oil, fish oil, astaxanthin, and coenzyme Q10 [3]. Financial Performance of Vitalis - Vitalis reported revenues of 151.43 million NOK and 97.94 million NOK for 2024 and the first half of 2025, respectively, with net profits of 28.55 million NOK and 23.31 million NOK [4]. - The profit target for Vitalis in 2025 is set at no less than 31 million NOK [4]. Performance Commitments - The acquisition includes performance commitments, requiring Vitalis to achieve a net profit of at least 41.85 million NOK by 2027 and 56.50 million NOK by 2028, representing a growth of no less than 35% year-over-year [5]. - The acquisition price of 300 million NOK is expected to create significant goodwill, which carries a risk of impairment [5]. Strategic Goals - The acquisition aims to implement the company's brand incubation and management strategy, enhancing its capabilities in brand management, product development, and supply chain management in the health sector [5]. - Qingmu Technology plans to increase investments in brand incubation and management, focusing on health consumer products through various strategies, including joint ventures and acquisitions of overseas brands [5]. Revenue Growth - In the first half of 2025, Qingmu's brand incubation and management business generated approximately 230 million RMB, marking an 86.5% year-over-year increase, with its contribution to overall revenue rising from 22.9% to 34.8% [6]. - The brands Cumlaude Lab and ZUCCARI significantly contributed to this revenue growth, achieving over 70% and 95% year-over-year increases, respectively [6]. Overall Company Performance - For the first three quarters of 2025, Qingmu Technology reported revenues of 1.021 billion RMB, a 26.34% increase year-over-year, and a net profit of 79.62 million RMB, up 10.22% [7]. - The company's gross margin has improved significantly, reaching 56.33% in the first three quarters of 2025, up 5.25 percentage points from the same period in 2024 [8].

Summary of Aoki Technology's Conference Call Company Overview - **Company**: Aoki Technology - **Acquisition Target**: Omega Brand - **Acquisition Amount**: Approximately 200 million RMB for 65.83% stake Key Points Industry and Market Potential - The health supplement industry in China is projected to reach a total market size of approximately 400 to 450 billion RMB in 2024, with an annual growth rate of 15% to 20% [6][12] - The fish oil segment is particularly strong, with online sales reaching 8.2 billion RMB from January to October 2025, representing a 36% year-on-year growth [6] Acquisition Details - Aoki Technology will acquire Omega Brand through a two-step process: purchasing existing shares and increasing capital, totaling 150 million Norwegian Krone (approximately 100 million RMB) [3][8] - The valuation is based on a 10.8 times price-to-earnings ratio for 2024 net profit, which is expected to become more attractive with a projected annual growth rate of over 35% [2][8] Financial Impact - The acquisition is expected to add over 500 million RMB to Aoki's annual profits, with a net profit margin anticipated to exceed 10% [2][9] - Aoki aims for Omega Brand to achieve over 1 billion RMB in revenue by 2027-2028, with a target of 35% growth compared to 2025 [4][12] Strategic Integration - Aoki plans to enhance Omega's supply chain, improve R&D capabilities, and expand into global markets [10] - The company will leverage existing online and offline channels, aiming for a balanced sales distribution between both [11] Product Development and Marketing - Aoki will focus on extending product lines around seal oil, fish oil, and astaxanthin, targeting cardiovascular health and expanding into brain health and eye care [11][16] - The company intends to utilize its marketing resources and consumer insights to support the new brand's growth [26] Competitive Advantages - Aoki has a strong position in the seal oil market due to its close relationships with upstream suppliers, which provides a competitive edge [13][15] - The company plans to differentiate itself in the health supplement sector by enhancing R&D for various products [15] Future Outlook - Aoki's current market share in China is approximately 80%, with plans to expand into Southeast Asia, Europe, and the Americas [14] - The company expects to see an increase in net profit margins as brand scale effects become more pronounced, with a projected net profit margin exceeding 25% [22][28] Operational Strategy - The new acquisition will be operated independently by Aoki's wholly-owned subsidiary, with expectations of significant revenue contributions in the coming years [24][25] - Aoki is also considering expanding into health food products in the long term, while focusing on existing supplement lines in the short term [17] Sales Performance - During the Double Eleven shopping festival, Aoki achieved a sales completion rate of over 100%, with a lower return rate compared to the previous year [23] This summary encapsulates the strategic direction, financial implications, and market positioning of Aoki Technology following its acquisition of Omega Brand, highlighting the company's growth potential in the health supplement industry.

Key Points - MSCI announced the inclusion of 26 new Chinese stocks and the removal of 20 stocks from the MSCI China Index, effective after the market close on November 24, 2025 [2] - The Ministry of Finance and the People's Bank of China have included electronic savings bonds in the scope of personal pension products to support the development of a multi-tiered pension insurance system [3] - Sixteen hard technology-themed funds have been approved, including seven AI ETFs and three chip ETFs, indicating an influx of capital into the sector [4] - The first large-capacity all-solid-state battery production line in China has been completed, with plans for small-scale production tests and a target for mass production between 2027 and 2030 [5] - Alibaba and Meituan are set to release their financial reports on November 25 and November 28, respectively, along with reports from leading electric vehicle companies [6][7] - The Federal Reserve will release its Beige Book this week, with expectations of interest rate decisions from New Zealand and South Korea [8] Company News - Hillstone Networks expects to achieve large-scale sales and product delivery of its new generation security products equipped with ASIC chips by Q1 2026 [10] - Zhongjin Lingnan plans to acquire a 6.7784% stake in Zhongjin Copper and a 10.3333% stake in Zhongjin Rongsheng for a total consideration of 742 million yuan [11] - Jinfeng Technology is planning to acquire at least a 51% stake in Guangdong Lanyuan Technology, which will enhance its growth and profitability [12] - Nenghui Technology signed a contract for a new energy power battery assembly with an estimated total price of 100 million yuan [13] - JinkoSolar announced the mass production of its Tiger Neo 3.0 module, achieving a production efficiency of over 24.8% and a total order of 15 GW [14] - Qingmu Technology's subsidiary plans to acquire control of Vitalis, enhancing its competitiveness in the health supplement sector [16] - Jiahua Technology is planning to acquire a controlling stake in Shudun Technology, with stock suspension expected [17] Market Insights - China Merchants Securities maintains a cautious outlook, citing weak trading signals and mixed fundamental indicators [19] - CITIC Securities notes the market is in a "three-phase overlap," suggesting a wait-and-see approach until key economic meetings in December [20]

Core Viewpoint - Qingmu Technology (301110) is expanding its business through a significant acquisition, aiming to enhance its brand incubation and management strategy in the health and wellness sector [1][4]. Group 1: Acquisition Details - Qingmu Technology's subsidiary, Qingmu Singapore, signed a share purchase and subscription agreement to acquire 49.07% of the target company's shares from Norsund for 150 million Norwegian Krone (approximately 106 million RMB) and to subscribe for an additional 32.92% of new shares for the same amount [1]. - After the completion of this transaction, Qingmu Singapore will hold a total of 65.83% of the target company, becoming its controlling shareholder, and the target company will be included in Qingmu's consolidated financial statements [1]. Group 2: Business Model and Services - Qingmu Technology provides comprehensive e-commerce services, including e-commerce operation, channel distribution, and retail services, catering to well-known domestic and international brands [1][2]. - The company has established a complete e-commerce ecosystem, collaborating with major platforms such as Tmall, JD.com, Douyin, Xiaohongshu, and Vipshop, and offers a full range of services from traditional e-commerce operations to digital marketing and consumer engagement [2]. Group 3: Growth Strategy - The brand incubation and management business is identified as the company's second growth curve, with a focus on health consumer products. The company plans to invest more in this area and introduce overseas quality brands through various methods, including joint ventures and acquisitions [3]. - The company reported significant revenue growth for its incubated brands, with Cumlaude Lab and ZUCCARI achieving over 70% and 95% year-on-year growth, respectively, in the first half of 2025 [3]. Group 4: Future Outlook - The acquisition aims to strengthen the company's capabilities in brand management, research and development, production, and supply chain management in the health supplement sector, enhancing its competitive edge [4]. - Qingmu Technology aspires to become a "data and technology-driven retail service expert," focusing on the application of new technologies like AI to improve operational efficiency [3].

Group 1: Major Announcements - Jiahua Technology plans to acquire controlling stake in Shudun Technology through a combination of share issuance and cash payment, leading to a potential major asset restructuring, with stock suspension starting from November 24, 2025, for up to 5 trading days [2] - China Merchants Bank's wholly-owned subsidiary, China Merchants Financial Asset Investment Co., has received approval to commence operations with a registered capital of 15 billion yuan, focusing on market-oriented debt-to-equity swaps and equity investment pilot projects [3] - CITIC Bank's wholly-owned subsidiary, Xinyin Financial Investment Co., has also been approved to start operations with a registered capital of 10 billion yuan, targeting strategic emerging industries and specialized sectors for market-oriented debt-to-equity swaps and equity investments [4] Group 2: Stock Performance and Risks - Zhongshui Fishery's stock has seen a significant price increase followed by a potential decline, with a rolling P/E ratio of 77.53 and a P/B ratio of 13.48, indicating substantial deviation from industry averages and raising concerns over irrational trading behavior [5] - Caixin Development's stock has also experienced a price deviation exceeding 20%, with uncertainty surrounding the bankruptcy restructuring of its controlling and indirect controlling shareholders, which may affect the company's control dynamics [6] Group 3: Acquisitions and Strategic Moves - Zhongjin Lingnan has acquired minority stakes in its subsidiaries, purchasing 4.2095% of Zhongjin Copper for 242 million yuan and 10.3333% of Zhongjin Rongsheng for 365 million yuan, among other transactions, resulting in full ownership of Zhongjin Copper [7] - Baili Tianheng's drug application for Iza-bren, a first-in-class treatment for advanced or metastatic nasopharyngeal carcinoma, has been accepted by the National Medical Products Administration [8] - Jinfut Technology is planning to acquire at least 51% of Guangdong Lanyuan Technology through cash payment, which is expected to enhance the company's profitability and risk resistance [9] - Qingmu Technology's subsidiary plans to acquire control of Vitalis for 150 million Norwegian kroner (approximately 106 million yuan), aiming to strengthen its position in the health and nutrition supplement market [12] - Zhongding Co. is entering a strategic partnership with Fourier for humanoid robot components, enhancing its product development capabilities [11] Group 4: Leadership Changes - Guiguan Network's chairman Chen Yu has resigned due to work changes, with a new candidate recommended to take over the chairman role [13] Group 5: Shareholding Changes - Shen Shui Haina's shareholder plans to reduce holdings by up to 1% within three months, while other shareholders of Guangli Micro plan to reduce holdings by up to 2.2359% [14][15] - Andar Intelligent's shareholder intends to reduce holdings by up to 2.7401% within three months [16] Group 6: Contracts and Orders - Nenghui Technology has signed a contract for a new energy power battery assembly with an estimated total price of 100 million yuan [17] - Jinko Solar has achieved cumulative orders of 15GW for its Tiger Neo3.0 module, which has a production efficiency exceeding 24.8% and a maximum power output of 670W [18]

标的公司主要从事高端健康营养补充剂的研发、生产及销售，旗下拥有Noromega等品牌，主要产品包 括海豹油、鱼油、虾青素、辅酶Q10等系列产品。本次并购目的是落实公司品牌孵化及管理业务发展战 略，加强公司在大健康赛道的布局和竞争力。本次交易完成后，将增强公司在品牌管理、健康营养补充 剂产品的研发、生产及供应链管理等方面的综合能力，并补充公司旗下自有品牌，以及公司的全资子公 司将成为Noromega品牌的中国区总经销商，将有利于提升公司的持续盈利能力。 智通财经APP讯，青木科技(301110.SZ)发布公告，公司的全资子公司QINGMU PTE.LTD.(简称"青木新 加坡")与Norsund Gruppen AS(简称"Norsund")、YunlinZHAN签署《股份购买及认购协议》，与 Norsund、Yunlin ZHAN及Vitalis Pharma AS(简称"Vitalis"或"标的公司")签署《新股认购协议》，以及相 关附属协议(《股份购买及认购协议》、《新股认购协议》及相关附属协议合称"收购协议")。根据收购 协议，青木新加坡将以1.5亿挪威克朗(约合人民币1.06亿元)现金购买Norsun ...

Group 1 - The core point of the news is that Qingmu Technology's subsidiary, Qingmu PTE. LTD., has signed a share purchase and subscription agreement to acquire a 49.0662% stake in Vitalis Pharma AS for 150 million Norwegian Krone (approximately 106 million RMB) and to subscribe for an additional 32.9157% stake for the same amount, resulting in a total ownership of 65.8314% and making it the controlling shareholder of the target company [1][2] Group 2 - The target company specializes in the research, production, and sales of high-end health nutritional supplements, with brands such as Noromega, and its main products include seal oil, fish oil, astaxanthin, and coenzyme Q10 [2] - The purpose of the acquisition is to implement the company's brand incubation and management strategy, enhancing its competitiveness in the health sector [2] - Post-transaction, the company will strengthen its capabilities in brand management, product research and development, production, and supply chain management, and will become the general distributor for the Noromega brand in China, which is expected to improve its sustainable profitability [2]

Core Insights - JD Health and Noromega have announced a deep cooperation to launch Noromega's annual million-unit premium seal oil product on JD Health's global health new product online debut platform, aiming to enhance the marine health food quality ecosystem and promote the dietary nutrition industry towards refinement and specialization [1][2]. Group 1: Company Collaboration - JD Health has chosen to collaborate with Noromega due to its outstanding product quality and control capabilities in the marine nutrition category [2]. - Noromega's seal oil is sourced from high-quality raw materials in the pristine waters of the Arctic Circle and has received ORIVO 100% pure seal oil certification, setting a new quality benchmark in the marine nutrition category [2]. Group 2: Product Launch and Market Strategy - The collaboration marks the launch of the premium seal oil series, which reflects Noromega's commitment to enhancing product quality standards, particularly in core categories like seal oil [2]. - JD Health plans to continue partnering with global nutrition brands like Noromega to ensure the precise introduction and sustained growth of global nutrition new products in the Chinese market, providing consumers with scientific, safe, and effective health products and nutritional solutions [2].

Group 1: Blue Economy and Health Industry Cooperation - The China-Norway Blue Economy and Health Industry Cooperation Seminar was successfully held during the 2025 China International Service Trade Fair, focusing on themes such as blue economy, marine technology, agricultural technology, health industry, and sustainable development [1] - A cooperation agreement was signed between China Road and Bridge Corporation and Norway's Pure Salmon Technology, expanding collaboration in aquaculture and infrastructure [1][7] Group 2: Service Industry and Trade Growth - The service industry has become a new engine for global economic growth, with its share of global GDP rising to 68% and service trade growth outpacing goods trade, increasing from 20.6% in 2013 to 25% in 2023 [2] - Beijing has implemented over 70 national breakthrough policies and attracted more than 8,000 foreign enterprises, utilizing over $66 billion in foreign investment, accounting for 8.4% of the national total [2][3] Group 3: Nutritional Health Food Market Potential - The nutritional health food industry in China is experiencing high-quality development, with market size growing from 99.3 billion yuan in 2013 to 328.3 billion yuan in 2023, a compound annual growth rate of 13%, and expected to exceed 800 billion yuan by 2027 [4] - In the first half of 2025, China's nutritional health food trade totaled $6.233 billion, with imports reaching $3.981 billion, reflecting a year-on-year growth of 10.3% and 10.5% respectively [4] Group 4: Import Trends and Consumer Demand - Norway ranked 16th among countries exporting nutritional health foods to China in the first half of 2025, with a trade total of $5.616 million, showing a year-on-year decline of 8.1% [4] - The Chinese market for imported cross-border health products has formed five core segments, with Norwegian brands holding significant positions in the cardiovascular and oral beauty sectors [5] Group 5: Green Agriculture and Sustainable Development - China Road and Bridge Corporation aims to establish a "green granary" in collaboration with Pure Salmon Technology, focusing on sustainable aquaculture and infrastructure development [6][8] - The partnership will involve creating a demonstration project for Atlantic salmon aquaculture in China, integrating advanced Norwegian technologies in automated feeding and fish disease diagnosis [8]